Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.80 | 12.90 | 0.15% |
| CAC 40 | 7,789.46 | 1.36 | 0.02% |
| DAX 40 | 23,972.81 | 65.38 | -0.27% |
| Dow JONES (US) | 42,101.57 | 2.87 | 0.01% |
| FTSE 100 | 8,726.32 | 0.31 | 0.00% |
| HKSE | 23,573.38 | 315.07 | 1.35% |
| NASDAQ | 19,244.89 | 143.95 | 0.75% |
| Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
| NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
| S&P 500 | 5,913.02 | 24.47 | 0.42% |
| S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
| SSE Composite Index | 3,363.45 | 23.51 | 0.70% |